STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Completed
- Lymphoma, Large B-Cell, Diffuse
- Gene Expression Profiling
- Gene expression profile
- Shanghai, Shanghai, ChinaYian Zhang
2022-03-31
Mar 31, 2022S
Completed
- Lymphoma, Large B-Cell, Diffuse
- FDG PET radiomic feature evaluation
- Hangzhou, Zhejiang, ChinaSecond Affiliated Hospital, School of Medicine, Zhejiang Univers
2021-09-27
Sep 27, 2021H
Recruiting
- Lymphoma, Large B-Cell, Diffuse
- Copenhagen, DenmarkDepartment of Hematology, Rigshospitalet
2022-01-12
Jan 12, 2022W
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma - 2022
Completed
- Lymphoma, Large B-Cell, Diffuse
- Brentuximab vedotin
- Lenalidomide
- Saint Louis, Missouri
- +1 more
2022-02-16
Feb 16, 2022R
Recruiting
- Lymphoma, Large B-Cell, Diffuse
- +2 more
- PD-1 Inhibitor Tislelizumab maintenance therapy
- Shanghai, Shanghai, ChinaRuijin Hospital
2021-11-14
Nov 14, 2021U
Completed
- Lymphoma, B-Cell
- Montpellier, FranceUh Montpellier
2021-11-12
Nov 12, 2021P
Recruiting
- Lymphoma, Large B-Cell, Diffuse
- Digital Health Coaching
- Columbus, OhioOhio State University Comprehensive Cancer Center
2022-01-19
Jan 19, 2022U
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Pembrolizumab
- +4 more
- (no location specified)
2022-02-02
Feb 2, 2022N
Completed
- Lymphoma, Large-Cell, Anaplasitc
- +4 more
- Anti-CD30-CAR T cells
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-01-27
Jan 27, 2022C
Not yet recruiting
- Lymphoma, Non-Hodgkin
- +3 more
- (no location specified)
2021-07-20
Jul 20, 2021U
Recruiting
- Pneumococcal Infections
- Lymphoma, Large B-Cell, Diffuse
- Anti-pneumococcal vaccination with prime-boost strategy in patients with diffuse large B cell lymphoma
- Tours, FranceGYAN
2021-05-17
May 17, 2021R
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- (no location specified)
2021-12-27
Dec 27, 2021N
Active, not recruiting
- Lymphoma, AIDS-related
- Lymphoma, Large B-Cell, Diffuse
- Rituximab
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-03-11
Mar 11, 2022J
Available
- Lymphoma, Large B-Cell, Diffuse
- Nonconforming Lisocabtagene Maraleucel
- (no location specified)
2022-01-11
Jan 11, 2022F
Recruiting
- Diffuse Large B Cell Lymphoma
- Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
2022-03-13
Mar 13, 2022T
Active, not recruiting
- Lymphoma, B-Cell
- San Antonio, TexasMays Cancer Center, UT Health San Antonio
2022-03-09
Mar 9, 2022A
No longer available
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
- Loncastuximab Tesirine
- (no location specified)
2021-05-10
May 10, 2021C
Not yet recruiting
- Non-GCB/ABC Diffuse Large B-Cell Lymphoma
- With and Without MyD88 and/or CD79B Mutations
- (no location specified)
2022-04-01
Apr 1, 2022B
Not yet recruiting
- Relapsed Diffuse Large B-cell Lymphoma
- loncastuximab tesirine
- Detroit, MichiganBarbara Ann Karmanos Cancer Institute
2022-01-24
Jan 24, 2022U
Completed
- Diffuse, Large B-Cell, Lymphoma
- Los Angeles, CaliforniaUSC Norris Comprehensive Cancer Center
2021-11-15
Nov 15, 2021C
Recruiting
- Diffuse Large B Cell Lymphoma
- 18F-FDG PET SCAN
- MRI DIFFUSION
- Nice, FranceCentre antoine-LACASSAGNE
2021-11-09
Nov 9, 2021R
Not yet recruiting
- Lymphoma, Large B-Cell, Diffuse
- +2 more
- PD-1 Inhibitor Tislelizumab maintenance therapy
- Shanghai, Shanghai, ChinaRuijin Hospital
2021-03-15
Mar 15, 2021D
Recruiting
- Diffuse Large B Cell Lymphoma
- +2 more
- Boston, MassachusettsDana-Farber Cancer Institute
2021-09-08
Sep 8, 2021M
Active, not recruiting
- Large B-Cell Diffuse Lymphoma
- Oral azacitidine
- R-ICE
- Charleston, South CarolinaMedical University of South Carolina
2022-03-31
Mar 31, 2022N
Completed
- Relapsed Non Hodgkin Lymphoma
- Refractory Lymphoma
- Taipei, TaiwanNational Taiwan University Hospital
2021-08-08
Aug 8, 2021